Startup
Programs: Brandon BioCatalyst (CUREator)
Every investor coverage indicates participated in a round Drug discovery platform targeting polynucleotides raised.
| Investor | Rounds | Invested |
|---|---|---|
| Brandon BioCatalyst | Accelerator | - |
Companies Drug discovery platform targeting polynucleotides acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Drug discovery platform targeting polynucleotides. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Biotech incubator CUREator's second round distributes $12 million among 19 health-focused startups, supported by government funding, while a new MedTech program backed by $50 million arrives later in the year.
CUREator, the national biotech incubator operated by Brandon BioCatalyst, selects 19 projects for its second funding round worth $12 million, and a $50 million MRFF award will add a MedTech stream.